RxDoctor Payments Data

Frank Tursi, DO

Family Medicine · Erie, PANPI 1568409050

Payments from drug & device makers

$5,918in general payments, 2019–2025

Across 367 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$744
  • AbbVie$699
  • Novo Nordisk$678
  • Pfizer$631
  • Boehringer Ingelheim$580
  • Merck$443
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,85499%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,918 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$12,152
Medicare patients
50
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol28$31,194
EliquisApixaban27$16,535
TradjentaLinagliptin15$15,958
TrulicityDulaglutide13$12,499
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,704
Simvastatin163$2,058
SynthroidLevothyroxine Sodium18$1,243
Omeprazole69$1,227
Metoprolol Succinate49$942
Rosuvastatin Calcium52$722
Gabapentin26$677
Pantoprazole Sodium71$590
Atorvastatin Calcium109$575
Metformin Hcl99$568
Ezetimibe35$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$234$31,19428 claims
PfizerEliquis$631$16,53527 claims
Boehringer IngelheimTradjenta$580$15,95815 claims
Lilly USA, LLCTrulicity$744$12,49913 claims
GSKTrelegy Ellipta$178$9,70413 claims
AbbVieSynthroid$699$1,24318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →